Key points are not available for this paper at this time.
We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors DPP4i, glucagon-like peptide-1 receptor agonists GLP1a) in patients with and without chronic kidney disease (CKD).
Narasaki et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: